#Behcet’s #syndrome is increasing in the UK ? ⬆️ Detection ? Changing population demographics ? Other reasons Poster discussion POS0258 #EULAR2024 @RheumNow @eular_org @Pr1yankaC https://t.co/SEzmJnFMhM

• https://twitter.com/Janetbirdope/status/1801530101282070779/photo/1
• https://twitter.com/Janetbirdope/status/1801530101282070779/photo/1

When would I use #Aclasta vs #Prolia since #denosumab has LESS #fractures ▶️younger women with #osteoporosis requiring Rx due to long safety ▶️less wearing off when stopping it ▶️noncompliant Pts as prolia reverses effect when dose is missed @RheumNow #EULAR2024 @eular_org https://t.co/0RTGx0sCTd

• https://twitter.com/janetbirdope/status/1801588758711541852

Agree! Liz Volkmann said it straight Unsustainable RCTs in ILD trials in #scleroderma Why Can’t recruit ~same pool of early #dcSSc design RCT UNETHICAL a to have a progressing #scleroderma-ILD Pt on failed background #MMF + placebo for 1 yr 🙏🏻 #EULAR2024 @RheumNow @eular_org https://t.co/29oFEazwmM

• https://twitter.com/Janetbirdope/status/1801594550097506713/photo/1

I think if we’re worried about JAK inhibitor safety, we need to be doing it right. I wrote this for @RheumNow for #EULAR2024 ahead of my debate against @Janetbirdope, but also drew my inspiration from @RADoctor in @ACR_Journals - a must read: https://t.co/RA6ktQAzqO https://t.co/lltDbtxpAg

• The Art of Communicating Risk and Benefit to Promote Shared Decision‐Making, In…
• https://twitter.com/rheumnow/status/1801615707999756628

🗓️ Our abstract on psychosocial determinants of health in #RheumatoidArthritis will be presented at #EULAR2024 📹 Watch my video on @RheumNow for a sneak preview! 📍 Join me to hear more on #PARE Poster Tour IV, Friday 14th June, 12:00 - 13:00 CEST https://t.co/rDTJVukD6j

• The Role of Psychosocial Determinants in the Management of Rheumatoid Arthritis

➡️POS0591 Are there sex differences in risk & outcomes of stroke in patients with #RA? 📈Stroke risk in RA increased compared to general population 🫀Not fully explained by traditional risk factors or AF 📊Stroke-related mortality differs in women vs men @RheumNow #EULAR2024

POS0592 Increased overall & cause-specific mortality in population-based cohort of people with incident #RA Higher mortality in RA vs gen pop but this has decreased after 2000 & better 10-year survival Severe causes of mortality incl cardiac higher in RA EULAR2024 @RheumNow

POS1035 FVC & risk of lung transplant & mortality in #RAILD 50% pts had FVC % predicted decline in ~6.5yrs 2/3 identified groups more strongly assoc w transplant or ILD-related death than INBUILD definition ➡️marked heterogeneity in ILD progression #EULAR2024 @RheumNow

#EULAR2024 POS1245 Healthcare Administrative Data in Italy showed despite prevalence of 3.8/10,000, heathcare cost in #Sjogren was 3 x higher than the general population due to active disease & comorbidities. Call for better MDT approach in management @RheumNow https://t.co/EevoT4jkqr

• https://twitter.com/Yuz6Yusof/status/1801665949319283150/photo/1

important session worth reading the full recommendations - TNF tick of approval @RheumNow #EULAR2024 https://t.co/ORDocVie11

• https://twitter.com/drpnash/status/1801664265461338298/photo/1

#EULAR2024 POS1420 A cohort study with 1/3 each with GCA, PMR and GCA+PMR found that at 6mth, 16% of patients had new diabetes/diabetes worsened. Worse in GCA+PMR group with the greatest GC accumulation. Call for better GC-sparing strategy @RheumNow https://t.co/ex7u83bVfj

• https://twitter.com/Yuz6Yusof/status/1801662770636591394/photo/1

#EULAR2024 POS0742 A single cohort study showed for non-criteria #APS, cardiac manifestation (valvular dysfunction & regurgitation) was more common in Triple Ab+ vs Non-Triple Ab. We should monitor and consider an echocardiogram for this group of patient @RheumNow https://t.co/VxFUSpjaG1

• https://twitter.com/Yuz6Yusof/status/1801658685774598633/photo/1

Active day of learning and discussion with a Round Up from Day 3 of #EULAR2024 with @RheumNow https://t.co/yzLsPNDM5d

• https://twitter.com/synovialjoints/status/1801657394243518562/photo/1

#EULAR2024 Please find my short blog on the Impact of Safety Warning Update on the use of JAK-inhibitors @RheumNow https://t.co/Z4pujQRQ9h https://t.co/QRUnJInblH

• Impact of regulatory warning on JAK inhibitors | RheumNow
• https://twitter.com/Yuz6Yusof/status/1801655701107790163/photo/1

#EULAR2024 POS0024 Lymphopenia, anemia, & low Plt are assoc with disease activity & damage accrual in #lupus. Post-hoc analysis of RCTs + LTE showed Anifrolumab normalised these Haem parameters vs PBO. May improve fatigue-associated with anaemia @RheumNow https://t.co/GF8aKU0Z5x

• https://twitter.com/Yuz6Yusof/status/1801654266823671968/photo/1